PGLYRP4

Across TCGA pan-cancer cohorts, PGLYRP4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PGLYRP4 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PGLYRP4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PGLYRP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, LIHC, and UCEC are the cancer types where PGLYRP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	IV	0.056	0.649	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.118	0.696	.003	6	view →
UCEC	DFS	Median	All	1.000	0.830	.027	6	view →
LGG	DFS	Median	All	0.328	0.731	.017	3	view →
LUAD	DFS	Median	II,III,IV	0.098	0.651	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PGLYRP4–COAD (OS)

Open the COAD breakdown →